Education
About Us
Working with TipRanks
Follow Us
XBI - AI Analysis
Top Page
SPDR S&P BIOTECH ETF (XBI)
Rating:59Neutral
Price Target:
$115.00
Positive Factors
Strong Year-to-Date Performance
The ETF has delivered solid gains so far this year, indicating positive momentum in the biotech sector.
Low Expense Ratio
The fund charges a relatively low fee, making it cost-effective for investors compared to many other ETFs.
Top Holdings Showing Strength
Several of the largest positions, such as Ionis Pharmaceuticals and Insmed, have shown strong year-to-date performance.
Negative Factors
Sector Over-Concentration
The ETF is heavily focused on the healthcare sector, which limits diversification and increases exposure to industry-specific risks.
Geographic Concentration
With nearly all assets invested in U.S. companies, the fund lacks global diversification and is vulnerable to domestic market fluctuations.
Mixed Performance Among Top Holdings
Some key holdings, such as Vertex Pharmaceuticals and Exact Sciences, have shown weaker year-to-date performance, which could drag on overall returns.
XBI vs. SPDR S&P 500 ETF (SPY)
AUM6.81B
RegionNorth America
Expense Ratio0.35%
Beta1.09
IssuerSPDR
Inception DateJan 31, 2006
Dividend Yield0.04%
Asset ClassEquity
Index TrackedS&P Biotechnology Select Industry
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume9,713,204
30 Day Avg. Volume9,533,448
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
158.00Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering130
XBI Summary
The SPDR S&P Biotech ETF (XBI) is a fund that focuses on the biotechnology sector, part of the health care industry. It includes a mix of companies, from established names like Amgen and Vertex Pharmaceuticals to smaller, innovative firms working on cutting-edge medical advancements like gene editing and personalized medicine. This ETF offers a way to invest in the growth potential of biotech, a field known for driving transformative health care solutions. However, new investors should be aware that the biotech sector can be volatile, as stock prices often depend on the success of clinical trials and regulatory approvals.
How much will it cost me?The SPDR S&P Biotech ETF (XBI) has an expense ratio of 0.35%, meaning you’ll pay $3.50 per year for every $1,000 invested. This expense ratio is slightly higher than average because the fund is actively managed with an equal-weighted structure, which requires more frequent adjustments compared to passively managed ETFs.
What would affect this ETF?The SPDR S&P Biotech ETF (XBI) could benefit from advancements in biotechnology, such as breakthroughs in gene editing and personalized medicine, which drive innovation and growth in the sector. However, it may face challenges from regulatory hurdles, high research costs, and potential economic downturns that could impact funding and investor sentiment in the biotech industry.
XBI Top 10 Holdings
The SPDR S&P Biotech ETF (XBI) is a dynamic play on the U.S. biotechnology sector, showcasing a diverse mix of established players and emerging innovators. Recent performance has been buoyed by companies like Insmed and Ionis Pharmaceuticals, which are riding strong technical momentum and positive clinical trial results. Revolution Medicines is also showing promise with advancements in its pipeline, despite ongoing financial challenges. However, stalwarts like Amgen and Vertex Pharmaceuticals have been more subdued, with mixed signals and some short-term volatility. With nearly all its exposure in health care, this fund is a concentrated bet on biotech breakthroughs.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Avidity Biosciences | 2.45% | $167.57M | $10.16B | 61.15% | 54 Neutral | |
| Revolution Medicines | 2.11% | $144.50M | $10.85B | 14.89% | 52 Neutral | |
| Crispr Therapeutics AG | 2.00% | $136.75M | $5.69B | 30.52% | 54 Neutral | |
| BridgeBio Pharma | 1.98% | $135.41M | $12.74B | 180.03% | 55 Neutral | |
| Regeneron | 1.92% | $130.92M | $68.61B | -29.25% | 79 Outperform | |
| Exact Sciences | 1.88% | $128.50M | $11.88B | -10.96% | 63 Neutral | |
| Ionis Pharmaceuticals | 1.87% | $127.81M | $11.46B | 83.09% | 57 Neutral | |
| Insmed | 1.84% | $125.95M | $35.29B | 137.50% | 57 Neutral | |
| Natera | 1.82% | $124.14M | $26.46B | 52.14% | 70 Neutral | |
| Vertex Pharmaceuticals | 1.77% | $120.87M | $106.97B | -12.18% | 75 Outperform |
XBI Technical Analysis
Positive
―
Price Trends
99.84
Positive
92.86
Positive
88.49
Positive
Market Momentum
3.35
Negative
71.03
Negative
82.15
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XBI, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 107.59, equal to the 50-day MA of 99.84, and equal to the 200-day MA of 88.49, indicating a bullish trend. The MACD of 3.35 indicates Negative momentum. The RSI at 71.03 is Negative, neither overbought nor oversold. The STOCH value of 82.15 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XBI.
XBI Peer Comparison
Comparison Results
Performance Comparison
XBI
SPDR S&P BIOTECH ETF
111.91
14.93
15.39%
IBB
iShares Biotechnology ETF
―
―
―
IHI
iShares U.S. Medical Devices ETF
―
―
―
IYH
iShares U.S. Healthcare ETF
―
―
―
FHLC
Fidelity MSCI Health Care Index ETF
―
―
―
FBT
First Trust NYSE Arca Biotechnology Index Fund
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents